Clinical trials designed to test the cardiovascular safety of the new antidiabetic drug class of GLP-1 analogs surprisingly revealed that treatment of type 2 diabetes mellitus with a long-acting GLP-1 analog leads to less cardiovascular events compared to standard care [4]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.